
	Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: A post-marketing surveillance study.(Studies) : An article ... of Dermatology, Venereology and Leprology $5.95	Overview on desonide 0.05%: a clinical safety profile.(ARTICLES) : An article from: Journal of Drugs in Dermatology $5.95


Overview on desonide 0.05%: a clinical safety profile Abstract Desonide (as a cream, ointment, or lotion formulation) is widely used for the treatment of steroid-responsive dermatoses. This paper provides ... From Journal of Drugs in Dermatology, 7/1/04 by Vicky Kwan Wong

Iatrogenic contact dermatitis due to propylene glycol Introduction Iatrogenic allergic contact dermatitis to propylene glycol (PG) is an important factor to consider in recalcitrant dermatitis. PG is widely used as a vehicle in many different types From Journal of Drugs in Dermatology, 1/1/05 by Rebecca Lu

Once-daily Sebazole effective in treating seborrheic dermatitis Barrier Therapeutics released the results of two Phase III trials for its drug Sebazole, indicating the drug's effectiveness in the treatment of facial ... From Journal of Drugs in Dermatology, 3/1/04

David E. Cohen, M.D., M.P.H. Named to Connetics' Board of Directors; CEO Thomas Wiggans to Become Chairman Effective January 1, 2006 PALO ALTO, Calif. -- Connetics Corporation (NASDAQ:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, announced today the appointment of David E. Cohen From Business Wire, 12/20/05

Connetics Introduces 2006 Financial Guidance; Revises 2005 Fourth Quarter Guidance; Provides 2007 Outlook Conference Call Begins at 4:30 p.m. Eastern Time PALO ALTO, Calif. -- Connetics Corporation (Nasdaq:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, today introduced financial guidance for 2006, rev From Business Wire, 12/19/05

Connetics Names Gary Cain Director, Toxicology; Reports New Option Grant Under NASDAQ Marketplace Rule 4350 PALO ALTO, Calif. -- Connetics Corporation (NASDAQ:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, announced today that it has named Gary Cain to th From Business Wire, 12/15/05

Barrier Therapeutics Announces FDA Acceptance of Its New Drug Application for Sebazole(TM) Topical Gel Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced ... From Market Wire, 12/9/05

Connetics Names Srabasti Mukherjee Associate Director, Business Applications; Reports New Option Grant Under NASDAQ Marketplace Rule 4350 PALO ALTO, Calif. -- Connetics Corporation (NASDAQ:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, announced today that it has named Srabasti Mukher From Business Wire, 11/10/05

Home

Contact

Resources

Exchange Links

ebay